Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Non-Current Assets: 2018-2025

Historic Non-Current Assets for Bicycle Therapeutics (BCYC) over the last 7 years, with Sep 2025 value amounting to $11.4 million.

  • Bicycle Therapeutics' Non-Current Assets fell 44.58% to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year decrease of 44.58%. This contributed to the annual value of $17.2 million for FY2024, which is 37.91% down from last year.
  • Per Bicycle Therapeutics' latest filing, its Non-Current Assets stood at $11.4 million for Q3 2025, which was down 19.06% from $14.1 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Non-Current Assets registered a high of $37.0 million during Q1 2023, and its lowest value of $5.7 million during Q3 2021.
  • Its 3-year average for Non-Current Assets is $23.1 million, with a median of $22.5 million in 2024.
  • Its Non-Current Assets has fluctuated over the past 5 years, first spiked by 442.27% in 2022, then crashed by 44.58% in 2025.
  • Quarterly analysis of 5 years shows Bicycle Therapeutics' Non-Current Assets stood at $17.8 million in 2021, then skyrocketed by 84.20% to $32.8 million in 2022, then dropped by 15.52% to $27.7 million in 2023, then tumbled by 37.91% to $17.2 million in 2024, then plummeted by 44.58% to $11.4 million in 2025.
  • Its last three reported values are $11.4 million in Q3 2025, $14.1 million for Q2 2025, and $15.4 million during Q1 2025.